1921
Volume 101, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

The discovery and characterization of novel parasite antigens to improve the diagnosis of by serological methods and for accurate and rapid follow-up of treatment efficiency are still needed. TcTASV is a –specific multigene family, whose products are expressed on the parasite stages present in the vertebrate host. In a previous work, a mix of antigens from subfamilies TcTASV-A and TcTASV-C (Mix A + C) was sensitive and specific to identify dogs with active infection of high epidemiological relevance. Here, TcTASV-A and TcTASV-C were assayed separately as well as together (Mix A + C) in an ELISA format on human samples. The Mix A + C presented moderate sensitivity (78%) but high diagnostic accuracy with a 100% of specificity, evaluated on healthy, leishmaniasic, and infected patients. Moreover, antibody levels of pediatric patients showed—2 years posttreatment—diminished reactivity against the Mix A + C ( < 0.0001), pointing TcTASV antigens as promising tools for treatment follow-up.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.18-0936
2019-09-09
2020-09-24
Loading full text...

Full text loading...

/deliver/fulltext/14761645/101/5/tpmd180936.html?itemId=/content/journals/10.4269/ajtmh.18-0936&mimeType=html&fmt=ahah

References

  1. World Health Organization, 2015. Chagas disease in Latin America: an epidemiological update based on 2010 estimates. Wkly Epidemiol Rec 6: 3344.
    [Google Scholar]
  2. World Health Organization, 2012. Research priorities for Chagas disease, human African trypanosomiasis and leishmaniasis. World Health Organ Tech Rep Ser 975: 1100.
    [Google Scholar]
  3. Sguassero Y, Cuesta CB, Roberts KN, Hicks E, Comandé D, Ciapponi A, Sosa-Estani S, 2015. Course of chronic Trypanosoma cruzi infection after treatment based on parasitological and serological tests: a systematic review of follow-up studies. PLoS One 10: e0139363.
    [Google Scholar]
  4. Pinazo MJ et al., 2014. Biological markers for evaluating therapeutic efficacy in Chagas disease, a systematic review. Expert Rev Anti Infect Ther 12: 479496.
    [Google Scholar]
  5. Albareda M et al., 2018. Distinct treatment outcomes of antiparasitic therapy in Trypanosoma cruzi-infected children is associated with early changes in cytokines, chemokines, and T-cell phenotypes. Front Immunol 9: 115.
    [Google Scholar]
  6. Santamaría AL, De Rissio AM, Riarte A, Garavaglia PA, Bruballa AC, Rodríguez MA, Irazu LE, Ruiz AM, García GA, 2013. Use of an enzyme-linked immunosorbent assay that utilizes the Tc13Tul antigen of Trypanosoma cruzi to monitor patients after treatment with benznidazole. Diagn Microbiol Infect Dis 76: 197205.
    [Google Scholar]
  7. Zrein M et al., 2018. A novel antibody surrogate biomarker to monitor parasite persistence in Trypanosoma cruzi-infected patients. PLoS Negl Trop Dis 12: 116.
    [Google Scholar]
  8. Granjon E, Dichtel-Danjoy ML, Saba E, Sabino E, Campos de Oliveira L, Zrein M, 2016. Development of a novel multiplex immunoassay multi-cruzi for the serological confirmation of Chagas disease. PLoS Negl Trop Dis 10: 115.
    [Google Scholar]
  9. Viotti R et al., 2011. Impact of aetiological treatment on conventional and multiplex serology in chronic Chagas disease. PLoS Negl Trop Dis 5: e1314.
    [Google Scholar]
  10. Balouz V, Melli LJ, Volcovich R, Moscatelli G, Moroni S, Ballering G, Bisio M, Buscaglia CA, Altcheh J, 2017. The trypomastigote small surface antigen from Trypanosoma cruzi improves treatment evaluation and diagnosis in pediatric Chagas disease. J Clin Microbiol 55: 34443453.
    [Google Scholar]
  11. Tekiel V, Alba-Soto CD, González Cappa SM, Postan M, Sánchez DO, 2009. Identification of novel vaccine candidates for Chagas’ disease by immunization with sequential fractions of a trypomastigote cDNA expression library. Vaccine 27: 13231332.
    [Google Scholar]
  12. García EA, Ziliani M, Agüero F, Bernabó G, Sánchez DO, Tekiel V, 2010. TcTASV: a novel protein family in Trypanosoma cruzi identified from a subtractive trypomastigote cDNA library. PLoS Negl Trop Dis 4: 6.
    [Google Scholar]
  13. Bernabó G, Levy G, Ziliani M, Caeiro LD, Sánchez DO, Tekiel V, 2013. TcTASV-C, a protein family in Trypanosoma cruzi that is predominantly trypomastigote-stage specific and secreted to the medium. PLoS One 8: 110.
    [Google Scholar]
  14. Caeiro LD, Alba-Soto CD, Rizzi M, Solana ME, Rodriguez G, Chidichimo AM, Rodriguez ME, Sánchez DO, Levy GV, Tekiel V, 2018. The protein family TcTASV-C is a novel Trypanosoma cruzi virulence factor secreted in extracellular vesicles by trypomastigotes and highly expressed in bloodstream forms. PLoS Negl Trop Dis 12: 126.
    [Google Scholar]
  15. Floridia-Yapur N et al., 2016. The TcTASV proteins are novel promising antigens to detect active Trypanosoma cruzi infection in dogs. Parasitology 143: 13821389.
    [Google Scholar]
  16. Camussone C, Gonzalez V, Belluzo MS, Pujato N, Ribone ME, Lagier CM, Marcipar IS, 2009. Comparison of recombinant Trypanosoma cruzi peptide mixtures versus multiepitope chimeric proteins as sensitizing antigens for immunodiagnosis. Clin Vaccine Immunol 16: 899905.
    [Google Scholar]
  17. Monje-Rumi M et al., 2013. Benznidazole treatment in chronic children infected with Trypanosoma cruzi: serological and molecular follow-up of patients and identification of discrete typing units. Acta Trop 128: 130136.
    [Google Scholar]
  18. Sosa-Estani S, Segura EL, Ruiz AM, Velazquez E, Porcel BM, Yampotis C, 1998. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas’ disease. Am J Trop Med Hyg 59: 526529.
    [Google Scholar]
  19. Escribà JM, Ponce E, Romero AdeD, Viñas PA, Marchiol A, Bassets G, Palma PP, Lima MA, Zúniga C, Ponce C, 2009. Treatment and seroconversion in a cohort of children suffering from recent chronic Chagas infection in Yoro, Honduras. Mem Inst Oswaldo Cruz 104: 986991.
    [Google Scholar]
  20. Sánchez Negrette O, Sánchez Valdéz FJ, Lacunza CD, García Bustos MF, Mora MC, Uncos AD, Basombrío MA, 2008. Serological evaluation of specific-antibody levels in patients treated for chronic Chagas’ disease. Clin Vaccine Immunol 15: 297302.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.18-0936
Loading
/content/journals/10.4269/ajtmh.18-0936
Loading

Data & Media loading...

  • Received : 23 Nov 2018
  • Accepted : 21 Jul 2019
  • Published online : 09 Sep 2019
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error